repo author in-lin
dividend increas board author addtl repo
announc increas dividend along
board author addit share repurchas program
pay dividend vs quarterli dividend
dividend increas in-lin model sinc assum
dividend would grow mid-singl digit rang beyond
pfe board director share repo program expect util
time in-lin assumpt remain
current share repo author assum repurchas
common stock establish floor stock capit alloc
key prioriti return sharehold first
nine month dividend share repurchas
acceler open-market share repurchas note previous
see note titl thought meet manag
pfe capit alloc prioriti dividend growth ii share repurchas
iii intern invest follow potenti tuck-in acquisit maintain
ep support dcf downsid could come
clinical/regulatori commerci price risk sip outag upsid
pipelin sip resolut
return revenu growth conting pipelin execut
appear posit post sale ep growth
growth expect challeng weather
anoth issu steril inject product segment
long-term growth outlook heavili depend pipelin execut
project increment revenu
come nme total exposur greater given label expans assumpt
ibranc xeljanz/xr rang pipelin read-out
beyond determin level success pipelin opportun
 eli lilli buy expect three remain trial tanezumab
chronic low back pain tango read earli bavencio multipl
upcom read-out gastric nsclc bladder ovarian
xtandi arch mhspc read-out anticip late competit
front bavencio merck buy keytruda dec pdufa
merkel cell carcinoma prioriti review expect file tafamidi
fda action prioriti review click
analysi opportun expect manufactur disrupt
steril inject sip busi resolv new ceo dr albert
bourla succe ian read jan
valuat risk
arriv target price assum stock trade ep believ
multipl warrant due pfe anem growth outlook higher concentr sale
gener eh account sale view stock range-bound sinc manag
appear demonstr lack urgenc time pfe dividend yield
aggress share repurchas could add floor stock view dcf analysi yield
intrins valu per share
risk rate price target includ increas competit key growth product
ibranc xalkori inlyta sutent xtandi xeljanz bavencio price pressures/high discount
rebat demand payer govern greater expect gener price compress
legaci eh product peri-lo addit risk overpay larg
biopharma acquisit convers also note sourc upsid risk could includ earlier
expect transform drive sharehold return better expect perform
growth asset instanc eliqui posit blood thin market could add signific
upsid pfe allianc revenu xtandi could receiv boost sale perform
non-metastat segment prostat cancer market
compani mention note
compani buy john bori
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
analyst compens base upon stock price perform qualiti analysi commun skill
overal revenu profit firm includ invest bank revenu
matter polici practic firm prohibit offer favor research specif
research rate specif target price consider induc receipt busi
compens addit associ person prepar research report prohibit own
secur subject compani
rate price target histori pfizer inc pfe-u
strh rate system equiti secur
dissemin research
suntrust robinson humphrey strh seek make reason effort provid research report
simultan elig client report avail publish restrict access area
creat bluematrix
page
websit elig client request password institut investor corpor
member press may also receiv research via third parti vendor includ thomson reuter
bloomberg factset capit iq addit distribut may done sale personnel via
email fax electron mean regular mail
access third parti vendor research websit http //suntrustlibrari bluematrix com/client/
pleas email research depart
contact strh sale repres
rate system effect oct
strh rate equiti secur
rate rel broader market gener next month unless
buy stock total return expect outperform relev benchmark
hold stock total return expect perform line relev benchmark
next month unless otherwis indic
sell stock total return expect under-perform relev benchmark
next month unless otherwis indic
rate nr strh invest rate opinion stock
coverag suspend cs indic strh rate and/or target price temporarili
suspend due applic regul and/or strh manag discret previous publish
rate target price reli upon
strh analyst price target stock cover unless otherwis indic price
target repres analyst expect stock trade next month unless
otherwis indic analyst believ insuffici valuat driver and/or invest
catalyst deriv posit neg invest view may elect approv strh
research manag assign target price likewis certain stock trade may
exhibit volatil wherebi assign price target would unhelp make invest decis
research manag approv analyst may refrain assign target sub-
legend rate price target histori chart
prior rate system oct
design base total return within period
buy total return low-beta secur
reduc total return neg low beta secur
neutral total return within bound
nr rate strh provid equiti research coverag
total return price appreci dividend price target within period unless
otherwis note beta defin secur averag beta less use bloomberg
page
suntrust robinson humphrey rate distribut
